← All trials
NCT05285137
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 14, 2022
- Primary completion
- Mar 22, 2023
- Completion date
- Mar 22, 2023
- First posted
- Mar 17, 2022
- Last posted
- Jun 29, 2022
- Enrollment
- 66
- Arms / groups
- 12 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cidara TherapeuticsLead sponsor
- Cidara TherapeuticsStudy director
- Janssen Pharmaceutica NVCollaborator
- Altasciences Company Inc.Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.